HPV16E7抗原的HLA-A2限制性细胞毒性T淋巴细胞表位的筛选与鉴定

目的 筛选和鉴定人工合成的人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞预测表位。方法 对预测的E7抗原人白细胞抗原A2分子限制性细胞毒性T细胞(CTL)表位运用标准Fmoc方案进行合成与纯化,采用标准⁵¹Cr释放试验检测特异性CTL诱导活性。结果 筛选并鉴定出E711-19(YMLDLQPET)和E7_49-57(RAHYNIVTF)2条人乳头瘤病毒16型E7抗原人白细胞抗原A2分子限制性CTL表位。结论 E711-19(YMLDLQPET)和E7_49-57(RAHYNIVTF)抗原性较强,有可能作为HPV感染治疗用肽疫苗的候选表位。

Screening and Identification of Predicted Epitopes of HLA-A2-restricted Cytotoxic T Lymphocytes Derived from the HPV16 E7 Antigen

Objective To screen and identify the predicted epitopes of synthesized predicted HLA-A2-restricted cytotoxic T lymphocytes (CTLs) derived from HPV16 E7 antigen. Methods The predicted epitopes of HLA-A2-restricted CTLs derived from HPV16 E7 antigen were synthesized and purified with Standard Fmoc assays, and the standard 51Cr release assay was used to determine their activities to induce specific CTL. Results Two epitopes of HLA-A2-restricted CTLs, namely E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) derived from HPV16 E7 antigen were identified. Conclusion E711-19 (YMLDLQPET) and E749-57 (RAHYNIVTF) have antigenicity, and may be the candidates for development of peptide vaccine in the treatment of HPV infections.